Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.

Molassiotis A, Cheng HL, Leung KT, Li YC, Wong KH, Au JSK, Sundar R, Chan A, Ng TR, Suen LKP, Chan CW, Yorke J, Lopez V.

Brain Behav. 2019 Jun;9(6):e01312. doi: 10.1002/brb3.1312. Epub 2019 May 7.

2.

Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.

Yeo F, Ng CC, Loh KWJ, Molassiotis A, Cheng HL, Au JSK, Leung KT, Li YC, Wong KH, Suen L, Chan CW, Yorke J, Farrell C, Bandla A, Ang E, Lopez V, Sundar R, Chan A.

Support Care Cancer. 2019 Apr 10. doi: 10.1007/s00520-019-04771-8. [Epub ahead of print]

PMID:
30972646
3.

Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.

Molassiotis A, Cheng HL, Lopez V, Au JSK, Chan A, Bandla A, Leung KT, Li YC, Wong KH, Suen LKP, Chan CW, Yorke J, Farrell C, Sundar R.

BMC Cancer. 2019 Feb 8;19(1):132. doi: 10.1186/s12885-019-5302-4.

4.

Saliva as a Diagnostic Tool in Oral Squamous Cell Carcinoma - a Systematic Review with Meta Analysis.

Hema Shree K, Ramani P, Sherlin H, Sukumaran G, Jeyaraj G, Don KR, Santhanam A, Ramasubramanian A, Sundar R.

Pathol Oncol Res. 2019 Apr;25(2):447-453. doi: 10.1007/s12253-019-00588-2. Epub 2019 Feb 2.

PMID:
30712193
5.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
6.

Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer.

Sundar R, Huang KK, Qamra A, Kim KM, Kim ST, Kang WK, Tan ALK, Lee J, Tan P.

Ann Oncol. 2019 Mar 1;30(3):424-430. doi: 10.1093/annonc/mdy550.

7.

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Ingles Garces AH, Ang JE, Ameratunga M, Chénard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U.

Eur J Cancer. 2018 Nov;104:32-38. doi: 10.1016/j.ejca.2018.08.019. Epub 2018 Oct 10.

8.

Single patch closure of multiple VSDs through right atrial approach.

Muthialu N, Balakrishnan S, Sundar R.

Indian Heart J. 2018 Jul - Aug;70(4):578-579. doi: 10.1016/j.ihj.2018.01.017. Epub 2018 Jan 11.

9.

Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.

Jain MR, Mohapatra J, Bandhyopadhyay D, Chatterjee A, Ghoshdastidar K, Patel D, Patel A, Bhayani H, Srivastava BK, Shedage SA, Kadam P, Sundar R, Patel H, Giri P, Patel P, Gupta L, Srinivas NR, Patel PR, Desai RC.

Cancer Chemother Pharmacol. 2018 Oct;82(4):635-647. doi: 10.1007/s00280-018-3653-1. Epub 2018 Jul 25.

PMID:
30046848
10.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept "3G" Trial.

Yong WP, Rha SY, Tan IB, Choo SP, Syn NL, Koh V, Tan SH, Asuncion BR, Sundar R, So JB, Shabbir A, Tan CS, Kim HS, Jung M, Chung HC, Ng MCH, Tai DW, Lee MH, Wu J, Yeoh KG, Tan P; Singapore Gastric Cancer Consortium (SGCC).

Clin Cancer Res. 2018 Nov 1;24(21):5272-5281. doi: 10.1158/1078-0432.CCR-18-0193. Epub 2018 Jul 25.

PMID:
30045931
11.

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.

Sundar R, Miranda S, Rodrigues DN, Chénard-Poirier M, Dolling D, Clarke M, Figueiredo I, Bertan C, Yuan W, Ferreira A, Chistova R, Boysen G, Perez DR, Tunariu N, Mateo J, Wotherspoon A, Chau I, Cunningham D, Valeri N, Carreira S, de Bono J.

Clin Colorectal Cancer. 2018 Dec;17(4):280-284. doi: 10.1016/j.clcc.2018.05.011. Epub 2018 Jun 8.

12.

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials.

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiriér M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT.

Eur J Cancer. 2018 Sep;101:55-61. doi: 10.1016/j.ejca.2018.06.003. Epub 2018 Jul 17.

13.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U.

Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245.

14.

Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.

Sundar R, Qamra A, Tan ALK, Zhang S, Ng CCY, Teh BT, Lee J, Kim KM, Tan P.

Gastric Cancer. 2018 Nov;21(6):1064-1070. doi: 10.1007/s10120-018-0851-9. Epub 2018 Jun 18.

PMID:
29915957
15.

Biomarkers for Homologous Recombination Deficiency in Cancer.

Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD.

J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085.

PMID:
29788099
16.

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

McVeigh TP, Sundar R, Diamantis N, Kaye SB, Banerji U, Lopez JS, de Bono J, van der Graaf WTA, George AJ.

Eur J Cancer. 2018 May;95:20-29. doi: 10.1016/j.ejca.2018.02.028. Epub 2018 Mar 31.

17.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.

Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP.

BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.

18.

Resisting resistance to cancer immunotherapy.

Lam WS, Wang LZ, Roudi R, Yong WP, Syn NL, Sundar R.

Thorac Cancer. 2018 May;9(5):507-508. doi: 10.1111/1759-7714.12614. Epub 2018 Mar 7. No abstract available.

19.

Teratoma Arising from Hepato Duodenal Ligament in the Newborn with Transection of Portal Vein, Hepatic Artery and Common Bile Duct: A Surgical Challenge.

Ravikumar VR, Rajamani G, Raju V, Sundar R, Ravikumar S, Maniam R.

J Indian Assoc Pediatr Surg. 2018 Jan-Mar;23(1):45-47. doi: 10.4103/jiaps.JIAPS_131_17.

20.

Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor β (TGFβ) signaling.

Karlsson T, Sundar R, Widmark A, Landström M, Persson E.

Prostate. 2018 May;78(6):446-456. doi: 10.1002/pros.23489. Epub 2018 Jan 31.

PMID:
29383751
21.

Genomic Analyses and Precision Oncology in Gastroesophageal Cancer: Forwards or Backwards?

Sundar R, Tan P.

Cancer Discov. 2018 Jan;8(1):14-16. doi: 10.1158/2159-8290.CD-17-1295.

22.

Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGFβ stimulation in cancer.

Gudey SK, Sundar R, Heldin CH, Bergh A, Landström M.

Oncotarget. 2017 Aug 9;8(58):97703-97726. doi: 10.18632/oncotarget.20097. eCollection 2017 Nov 17.

23.

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit.

Sundar R, Custodio A, Petruckevich A, Chénard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J.

Clin Oncol (R Coll Radiol). 2018 Mar;30(3):185-191. doi: 10.1016/j.clon.2017.11.011. Epub 2017 Dec 7.

24.

Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.

Brown JS, Sundar R, Lopez J.

Br J Cancer. 2018 Feb 6;118(3):312-324. doi: 10.1038/bjc.2017.376. Epub 2017 Nov 9. Review.

25.

Identification of appropriate QTc formula in beagle dogs for nonclinical safety assessment.

Patel S, Bhatt L, Patel R, Shah C, Patel V, Patel J, Sundar R, Bhatnagar U, Jain M.

Regul Toxicol Pharmacol. 2017 Oct;89:118-124. doi: 10.1016/j.yrtph.2017.07.026. Epub 2017 Jul 25.

PMID:
28751260
26.

Targeting ATR in cancer medicine.

Sundar R, Brown J, Ingles Russo A, Yap TA.

Curr Probl Cancer. 2017 Jul - Aug;41(4):302-315. doi: 10.1016/j.currproblcancer.2017.05.002. Epub 2017 May 17. Review.

PMID:
28662958
27.

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Sundar R, Hong DS, Kopetz S, Yap TA.

Cancer Discov. 2017 Jun;7(6):558-560. doi: 10.1158/2159-8290.CD-17-0087.

28.

Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Sundar R, Chénard-Poirier M, Collins DC, Yap TA.

Front Med (Lausanne). 2017 Apr 10;4:39. doi: 10.3389/fmed.2017.00039. eCollection 2017. Review.

29.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Dolly SO, Collins DC, Sundar R, Popat S, Yap TA.

Drugs. 2017 May;77(8):813-827. doi: 10.1007/s40265-017-0732-2. Review.

PMID:
28378229
30.

Limb Hypothermia for Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Pilot Study.

Sundar R, Bandla A, Tan SS, Liao LD, Kumarakulasinghe NB, Jeyasekharan AD, Ow SG, Ho J, Tan DS, Lim JS, Vijayan J, Therimadasamy AK, Hairom Z, Ang E, Ang S, Thakor NV, Lee SC, Wilder-Smith EP.

Front Oncol. 2017 Jan 10;6:274. doi: 10.3389/fonc.2016.00274. eCollection 2016.

31.

Emerging biomarkers for PD-1 pathway cancer therapy.

Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA.

Biomark Med. 2017 Jan;11(1):53-67. Epub 2016 Dec 12. Review.

PMID:
27936870
32.

Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics.

Collins DC, Sundar R, Lim JSJ, Yap TA.

Trends Pharmacol Sci. 2017 Jan;38(1):25-40. doi: 10.1016/j.tips.2016.10.012. Epub 2016 Nov 18. Review.

PMID:
27871777
33.

Combining Molecularly Targeted Agents: Is More Always Better?

Sundar R, Valeri N, Harrington KJ, Yap TA.

Clin Cancer Res. 2017 Mar 1;23(5):1123-1125. doi: 10.1158/1078-0432.CCR-16-2399. Epub 2016 Nov 10.

34.

Low Levels of NDRG1 in Nerve Tissue Are Predictive of Severe Paclitaxel-Induced Neuropathy.

Sundar R, Jeyasekharan AD, Pang B, Soong RC, Kumarakulasinghe NB, Ow SG, Ho J, Lim JS, Tan DS, Wilder-Smith EP, Bandla A, Tan SS, Asuncion BR, Fazreen Z, Hoppe MM, Putti TC, Poh LM, Goh BC, Lee SC.

PLoS One. 2016 Oct 7;11(10):e0164319. doi: 10.1371/journal.pone.0164319. eCollection 2016.

35.

Modular pump head design of diffused, metal, and hybrid pump geometry for diode-side-pumped high power Nd:YAG laser.

Sundar R, Ranganathan K, Hedaoo P, Bindra KS.

Appl Opt. 2016 Sep 20;55(27):7530-7. doi: 10.1364/AO.55.007530.

PMID:
27661579
36.

Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.

Wong AL, Sundar R, Wang TT, Ng TC, Zhang B, Tan SH, Soh TI, Pang AS, Tan CS, Ow SG, Wang L, Mogro J, Ho J, Jeyasekharan AD, Huang Y, Thng CH, Chan CW, Hartman M, Iau P, Buhari SA, Goh BC, Lee SC.

Oncotarget. 2016 Sep 27;7(39):64089-64099. doi: 10.18632/oncotarget.11596.

37.

Differential bleaching of corals based on El Niño type and intensity in the Andaman Sea, southeast Bay of Bengal.

Lix JK, Venkatesan R, Grinson G, Rao RR, Jineesh VK, Arul MM, Vengatesan G, Ramasundaram S, Sundar R, Atmanand MA.

Environ Monit Assess. 2016 Mar;188(3):175. doi: 10.1007/s10661-016-5176-8. Epub 2016 Feb 18.

PMID:
26887314
38.

Assessing attentional prioritization of front-of-pack nutrition labels using change detection.

Becker MW, Sundar RP, Bello N, Alzahabi R, Weatherspoon L, Bix L.

Appl Ergon. 2016 May;54:90-9. doi: 10.1016/j.apergo.2015.11.014. Epub 2015 Dec 28.

39.

Modular pump geometry for diode side-pumped high-power Nd:YAG rod laser.

Sundar R, Hedaoo P, Ranganathan K, Soni JK, Bindra KS, Oak SM.

Appl Opt. 2015 Nov 20;54(33):9855-62. doi: 10.1364/AO.54.009855.

PMID:
26836549
40.

To See or Not to See: Do Front of Pack Nutrition Labels Affect Attention to Overall Nutrition Information?

Bix L, Sundar RP, Bello NM, Peltier C, Weatherspoon LJ, Becker MW.

PLoS One. 2015 Oct 21;10(10):e0139732. doi: 10.1371/journal.pone.0139732. eCollection 2015.

41.

Front of Pack Labels Enhance Attention to Nutrition Information in Novel & Commercial Brands.

Becker MW, Bello NM, Sundar RP, Peltier C, Bix L.

Food Policy. 2015 Oct 1;56:76-86.

42.

Hypothermia for preventing chemotherapy-induced neuropathy - a pilot study on safety and tolerability in healthy controls.

Bandla A, Sundar R, Liao LD, Sze Hui Tan S, Lee SC, Thakor NV, Wilder-Smith EP.

Acta Oncol. 2016;55(4):430-6. doi: 10.3109/0284186X.2015.1075664. Epub 2015 Sep 11.

PMID:
26360921
43.

Nivolumab in NSCLC: latest evidence and clinical potential.

Sundar R, Cho BC, Brahmer JR, Soo RA.

Ther Adv Med Oncol. 2015 Mar;7(2):85-96. doi: 10.1177/1758834014567470. Review.

44.

Zinner syndrome: an uncommon cause of painful ejaculation.

Sundar R, Sundar G.

BMJ Case Rep. 2015 Mar 6;2015. pii: bcr2014207618. doi: 10.1136/bcr-2014-207618.

45.

Referral patterns for mediastinal staging with EBUS across a UK Lung Cancer Network: A report from the Manchester Cancer EBUS sub-group.

Evison M, Crosbie P, Morris J, Martin J, Shah R, Doran H, Hoyle J, Bailey S, Rana D, Sundar R, Booton R.

Lung Cancer. 2015 Apr;88(1):114-5. doi: 10.1016/j.lungcan.2015.02.001. Epub 2015 Feb 9. No abstract available.

PMID:
25703892
46.

TRAF6 promotes TGFβ-induced invasion and cell-cycle regulation via Lys63-linked polyubiquitination of Lys178 in TGFβ type I receptor.

Sundar R, Gudey SK, Heldin CH, Landström M.

Cell Cycle. 2015;14(4):554-65. doi: 10.4161/15384101.2014.990302.

47.

Efficacy of tranexamic acid as compared to aprotinin in open heart surgery in children.

Muthialu N, Balakrishnan S, Sundar R, Muralidharan S.

Ann Card Anaesth. 2015 Jan-Mar;18(1):23-6. doi: 10.4103/0971-9784.148316.

48.

Immunotherapy in the treatment of non-small cell lung cancer.

Sundar R, Soong R, Cho BC, Brahmer JR, Soo RA.

Lung Cancer. 2014 Aug;85(2):101-9. doi: 10.1016/j.lungcan.2014.05.005. Epub 2014 May 14. Review.

49.

TRAF6 stimulates the tumor-promoting effects of TGFβ type I receptor through polyubiquitination and activation of presenilin 1.

Gudey SK, Sundar R, Mu Y, Wallenius A, Zang G, Bergh A, Heldin CH, Landström M.

Sci Signal. 2014 Jan 7;7(307):ra2. doi: 10.1126/scisignal.2004207.

PMID:
24399296
50.

Evaluation of adverse effects of lisinopril and rosuvastatin on hematological and biochemical analytes in wistar rats.

Dodiya H, Kale V, Goswami S, Sundar R, Jain M.

Toxicol Int. 2013 May;20(2):170-6. doi: 10.4103/0971-6580.117261.

Supplemental Content

Loading ...
Support Center